Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct;27(10):6088-6091.
doi: 10.1111/dom.16662. Epub 2025 Jul 30.

Association between patient-reported eating behaviours and weight change: Secondary analyses of a randomized, double-blind trial comparing retatrutide and placebo in people with obesity or overweight

Chisom Kanu  1 , Qiwei Wu  1 , Jiat Ling Poon  1 , Iris Goetz  1 , Magaly Perez-Nieves  1 , Kristina Boye  1 , Corby K Martin  2 , Tamer Coskun  1 , Mark L Hartman  1
Affiliations

Association between patient-reported eating behaviours and weight change: Secondary analyses of a randomized, double-blind trial comparing retatrutide and placebo in people with obesity or overweight

Chisom Kanu et al. Diabetes Obes Metab. 2025 Oct.
No abstract available

Keywords: anti‐obesity drug; appetite control; patient‐reported outcomes; weight management.

PubMed Disclaimer

Conflict of interest statement

Chisom Kanu, Qiwei Wu, Jiat Ling Poon, Iris Goetz, Magaly Perez‐Nieves, Kristina Boye, Tamer Coskun, and Mark L. Hartman are employees and stockholders of Lilly. Corby K. Martin has been the primary investigator and co‐investigator on research contracts from Lilly, which were paid to his institution. His institution has also received funds via contracts with Lilly to provide advice on patient‐reported outcomes when designing studies. These agreements were not related to the current work. Lilly manufactures the drug studied in this paper.

Figures

FIGURE 1
FIGURE 1
Changes from baseline in Eating Inventory scores for (A) disinhibition, (B) perceived hunger, and (C) cognitive restraint at Weeks 24 and 48 by treatment group. LSM, least squares mean; SE, standard error. *p < 0.05; **p < 0.001 for within‐group change from baseline to Week 24 or 48; † p < 0.01 for retatrutide versus placebo. p values were not adjusted for multiple comparisons.
See this image and copyright information in PMC

References

    1. Seidell JC, Halberstadt J. The global burden of obesity and the challenges of prevention. Ann Nutr Metab. 2015;66(Suppl 2):7‐12. doi: 10.1159/000375143 - DOI - PubMed
    1. Bray GA, Kim KK, Wilding JPH, World Obesity Federation . Obesity: a chronic relapsing progressive disease process. A position statement of the world obesity federation. Obes Rev. 2017;18(7):715‐723. doi: 10.1111/obr.12551 - DOI - PubMed
    1. Abdelaal M, le Roux CW, Docherty NG. Morbidity and mortality associated with obesity. Ann Transl Med. 2017;5:161. doi: 10.21037/atm.2017.03.107 - DOI - PMC - PubMed
    1. Yuen MMA. Health complications of obesity: 224 obesity‐associated comorbidities from a mechanistic perspective. Gastroenterol Clin North Am. 2023;52:363‐380. doi: 10.1016/j.gtc.2023.03.006 - DOI - PubMed
    1. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP‐1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34:1234‐1247.e. doi: 10.1016/j.cmet.2022.07.013 - DOI - PubMed